Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum IL-2 inhibitor in mice. I. Increase during infection.

Literature DB >> 3899918

Serum IL-2 inhibitor in mice. I. Increase during infection.

Abstract

Serum from normal mice contains an inhibitor of interleukin-2 (IL-2) which probably interacts directly with IL-2. Athymic mice and normal mice kept under specific pathogen-free conditions do not show this activity, whereas mice infected with malaria parasites have increased serum levels of inhibitor. This IL-2 inhibitor may play an important part in regulating T-cell function.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1985 PMID： 3899918 PMCID： PMC1453670

Source DB: PubMed Journal: Immunology ISSN： 0019-2805 Impact factor: 7.397

14 in total

1. T-cell activation in murine malaria.

Authors: A N Jayawardena; G A Targett; E Leuchars; R L Carter; M J Doenhoff; A J Davies
Journal: Nature Date: 1975-11-13 Impact factor: 49.962

2. Effect of normal mouse serum on mouse lymphocyte transformation in vitro.

Authors: D S Nelson; C N Shneider
Journal: Eur J Immunol Date: 1974-02 Impact factor: 5.532

3. Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2.

Authors: M Malkovsky; G L Asherson; B Stockinger; M C Watkins
Journal: Nature Date: 1982-12-16 Impact factor: 49.962

Review 4. Malaria and alterations in immune reactivity.

Authors: W P Weidanz
Journal: Br Med Bull Date: 1982-05 Impact factor: 4.291

5. Cell-mediated immunity in mice vaccinated against malaria.

Authors: B J Cottrell; J H Playfair; B J De Souza
Journal: Clin Exp Immunol Date: 1978-11 Impact factor: 4.330

6. Anti-lymphocyte antibodies in lethal mouse malaria. II. Induction of an autoantibody specific suppressor T cell by non-lethal P. yoelii.

Authors: J B de Souza; J H Playfair
Journal: Clin Exp Immunol Date: 1983-10 Impact factor: 4.330

7. Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi.

Authors: A Harel-Bellan; M Joskowicz; D Fradelizi; H Eisen
Journal: Proc Natl Acad Sci U S A Date: 1983-06 Impact factor: 11.205

8. In vivo development of cytolytic T lymphocytes (CTL) to hapten-altered self: MIs-disparate cells facilitate the response by neutralizing IL 2 inhibitor.

Authors: S C Gautam; M L Hilfiker; J R Battisto
Journal: J Immunol Date: 1983-02 Impact factor: 5.422

9. Differential involvement of non-specific suppressor T cells in two lethal murine malaria infections.

Authors: R Lelchuk; V M Sprott; J H Playfair
Journal: Clin Exp Immunol Date: 1981-08 Impact factor: 4.330

10. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo.

Authors: C Hardt; M Röllinghoff; K Pfizenmaier; H Mosmann; H Wagner
Journal: J Exp Med Date: 1981-08-01 Impact factor: 14.307

20 in total

Review 1. The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors: R J Wills; B L Ferraiolo
Journal: Clin Pharmacokinet Date: 1992-12 Impact factor: 6.447

Review 2. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors: Iftekhar Mahmood; Martin D Green
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

Review 3. The relevance of pharmacokinetics in the development of biotechnology products.

Authors: S Toon
Journal: Eur J Drug Metab Pharmacokinet Date: 1996 Apr-Jun Impact factor: 2.441

Review 4. Roles of interferon produced in physiological conditions. A speculative review.

Authors: V Bocci
Journal: Immunology Date: 1988-05 Impact factor: 7.397

5. Helper and suppressor activities of an autoreactive mouse thyroglobulin-specific T-cell clone.

Authors: B R Champion; P Hutchings; S Davies; S Marshall-Clarke; A Cooke; I M Roitt
Journal: Immunology Date: 1986-05 Impact factor: 7.397

Review 6. Interactions of viruses with the immune system.

Authors: C A Mims
Journal: Clin Exp Immunol Date: 1986-10 Impact factor: 4.330

7. Serum IL-2 inhibitor in mice. II. Molecular characteristics.

Authors: D Male; R Lelchuk; S Curry; G Pryce; J H Playfair
Journal: Immunology Date: 1985-09 Impact factor: 7.397

8. Interleukin 2 inhibitor in synovial fluid.

Authors: P Emery; K C Gentry; A Kelso; I R Mackay
Journal: Clin Exp Immunol Date: 1988-04 Impact factor: 4.330

9. Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors: J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal: Clin Exp Immunol Date: 1986-08 Impact factor: 4.330

10. Increased plasma levels of soluble IL-2R are associated with severe Plasmodium falciparum malaria.

Authors: P H Jakobsen; S Morris-Jones; T G Theander; L Hviid; M B Hansen; K Bendtzen; R G Ridley; B M Greenwood
Journal: Clin Exp Immunol Date: 1994-04 Impact factor: 4.330